Primary Care Diabetes
Volume 1, Issue 1 , Pages 49-55 , February 2007

New global recommendations: A multidisciplinary approach to improving outcomes in diabetes

  • Margaret McGill

      Affiliations

    • Diabetes Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia
    • Corresponding Author InformationCorresponding author.
    • ,
  • Anne-Marie Felton

      Affiliations

    • Federation of European Nurses in Diabetes, 24 Holmesdale Avenue, London, SW14 7BQ, UK
    • ,
  • on behalf of the Global Partnership for Effective Diabetes Management

Received 21 April 2006 ,Accepted 28 July 2006.

References 

  1. International Diabetes Federation Diabetes Atlas, second ed., International Diabetes Federation, Brussels, 2003.
  2. Diabetes mellitus, Fact Sheet No 138, available at: http://www.who.int/mediacentre/factsheets/fs138/en/index.html, accessed August 18, 2005.
  3. Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. Diab. Obes. Metab. 1999;1(Suppl. 1):S1–S7
  4. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch. Intern. Med. 2001;161:1581–1586
  5. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diab. Care. 1998;21:1414–1431
  6. Jonsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002;45:S5–S12
  7. Gray RP, Yudkin JS. Cardiovascular disease in diabetes mellitus. In:  Pickup JC,  Williams G editor. Textbook of Diabetes. Oxford: Blackwell Sciences Ltd.; 1997;(Chapter 57)
  8. UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–1258
  9. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. 2000;321:405–412
  10. Writing Team For The Diabetes Control And Complications Trial/Epidemiology Of Diabetes Interventions And Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563–2569
  11. Writing Team for the DCCT/EDIC Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–2167
  12. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N. Engl. J. Med. 2003;348:2294–2303
  13. Del Prato S, Felton A-M, Munro N, et al. Improving glucose management: ten steps to get more patients with type 2 diabetes to goal. Recommendations from the Global Partnership for Effective Diabetes Management. Int. J. Clin. Pract. 2005;59:1345–1355
  14. American Diabetes Association. Standards of medical care in diabetes. Diab. Care. 2004;27(Suppl. 1):S15–S34
  15. European Diabetes Policy Group. A desktop guide to type 2 diabetes. Diab. Med. 1999;16:716–730
  16. Clinical guideline G. Management of type 2 diabetes: management of blood glucose, available at: http://www.nice.org.uk/.
  17. Asian-Pacific Type 2 Diabetes Policy Group. Type 2 Diabetes: Practical Targets and Treatments. third ed.. 2002;
  18. Latinamerican Diabetes Association (ALAD). Guidelines for the diagnosis, control and treatment of type 2 diabetes mellitus. Revista de la Asociacion Latinoamericana de Diabetes. 2000;8(Suppl. 1):101–167
  19. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335–342
  20. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia. 2002;45:S23–S28
  21. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003;348:383–393
  22. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann. Intern. Med. 2004;141:413–420
  23. Campbell IW. Need for intensive, early glycaemic control in patients with type 2 diabetes. Br. J. Cardiol. 2000;7:625–631
  24. Brown JB, Nichols GA. Glycemic burden of oral agent failure in type 2 diabetes. Diabetes. 2003;52(Suppl. 1):A61–A62
  25. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diab. Care. 2004;27:1535–1540
  26. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diab. Care. 2003;26:1408–1412
  27. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975–980
  28. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643–1649
  29. Kobayashi M. Effects of current therapeutic interventions on insulin resistance. Diab. Obes. Metab. 1999;1(Suppl. 1):S32–S40
  30. Global Guideline for Type 2 Diabetes, available at: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf, accessed January 16, 2006.
  31. Blonde L, Ginsberg BH, Horn S, et al. Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. Diab. Care. 2002;25:245–246
  32. Bailey CJ, Turner RC. Metformin. N. Engl. J. Med. 1996;334:574–579
  33. Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs. 1998;55:225–236
  34. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diab. Med. 1998;15:290–296
  35. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005–2012
  36. Rosenstock J, Porter LE, Heise M, O’Neill C, Kravitz B, Freed MI. The RESULT study in older type 2 diabetes: reaching durable glycemic goals with combination sulfonylurea and rosiglitazone. Diabetes. 2004;53(Suppl. 2):A160
  37. Sadur CN, Moline N, Costa M, et al. Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits. Diab. Care. 1999;22:2011–2017
  38. Codispoti C, Douglas MR, McCallister T, Zuniga A. The use of a multidisciplinary team care approach to improve glycemic control and quality of life by the prevention of complications among diabetic patients. J. Okla State Med. Assoc. 2004;97:201–204
  39. National Diabetes Education Program, Team care: comprehensive lifetime management for diabetes, Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, Georgia, U.S., 2001.
  40. Verlato G, Muggeo M, Bonora E, Corbellini M, Bressan F, de Marco R. Attending the diabetes center is associated with increased 5-year survival probability of diabetic patients: the Verona Diabetes Study. Diab. Care. 1996;19:211–213
  41. Muhlhauser I, Berger M. Evidence-based patient information in diabetes. Diab. Med. 2000;17:823–829
  42. Heisler M, Piette JD, Spencer M, Kieffer E, Vijan S. The relationship between knowledge of recent HbA1c values and diabetes care understanding and self-management. Diab. Care. 2005;28:816–822
  43. Lorig KR, Sobel DS, Ritter PL, Laurent D, Hobbs M. Effect of a self-management program on patients with chronic disease. Eff. Clin. Pract. 2001;4:256–262
  44. Gagliardino JJ, Etchegoyen G. A model educational program for people with type 2 diabetes: a cooperative Latin American implementation study (PEDNID-LA). Diab. Care. 2001;24:1001–1007
  45. Tuttleman M, Lipsett L, Harris MI. Attitudes and behaviors of primary care physicians regarding tight control of blood glucose in IDDM patients. Diab. Care. 1993;16:765–772

PII: S1751-9918(06)00006-4

doi: 10.1016/j.pcd.2006.07.004

Primary Care Diabetes
Volume 1, Issue 1 , Pages 49-55 , February 2007

Article Tools

* Image Usage & Resolution